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ABSTRACT:
The  PIM  family  of  oncogenic  serine/threonine  kinases  regulates  tumour  cell 
proliferation. To identify proliferative signaling pathways that are regulated by PIM 
kinases we analyzed gene expression differences in DU-145 and PC3 prostate cancer 
derived cells induced by treatment with the recently developed highly selective PIM 
kinase inhibitor M-110. This identified 97 genes the expression of which is affected 
by M-110 in both cell lines. We then focused on the M-110 induced up regulation of 
the MIG6 gene that encodes a negative regulator of EGFR signaling. Here we show 
that M-110 and the structurally unrelated PIM kinase inhibitor SGI-1776 up regulate 
MIG6 in DU-145 and PC3 cells. Knockdown of PIM-1 but not of PIM-2 or PIM-3 also 
up regulates MIG6 expression, which identifies MIG6 as a PIM-1 regulated gene. In 
agreement with the role of MIG6 protein as a negative regulator of EGFR signaling we 
found that M-110 treatment inhibits EGF induced EGFR activation and the activation of 
the downstream ERK MAPkinase pathway. The biological significance of these findings 
are demonstrated by the fact that co-treatment of DU-145 or PC3 cells with the EGFR 
tyrosine kinase inhibitor Gefitinib and M-110 or SGI-1776 has synergistic inhibitory 
effects on cell proliferation. These experiments define a novel biological function of 
PIM-1 as a co-regulator of EGFR signaling and suggest that PIM inhibitors may be used 
in combination therapies to increase the efficacy of EGFR tyrosine kinase inhibitors. 
INTRODUCTION
The PIM family of oncogenic serine/threonine 
kinases consists of three members, PIM-1, PIM-2 and 
PIM-3. The pim-1  proto-oncogene  was  first  identified 
as a locus frequently activated by proviral integration 
in Moloney murine leukemia virus induced mouse 
T-cell lymphomas and pim-2  was  identified  as  a  gene 
frequently activated in secondary transplants of virus 
induced  lymphomas.  Pim-3  was  identified  as  a  Pim-
1 and Pim-2 related kinase. The oncogenic nature of 
Pim-1 and Pim-2 was confirmed by the observation that 
transgenic mice over expressing these kinases in the 
lymphoid system developed lymphomas. Simultaneous 
over expression of c-myc further increased the frequency 
of lymphomagenesis [1]. PIM kinases are also involved 
in the development of solid tumors. PIM-1 and PIM-
2 are implicated in prostate cancer development [2, 3], 
PIM-1 is over expressed in head and neck squamous cell 
carcinoma and bladder cancer [4, 5] and PIM-3 is over 
expressed in colorectal, pancreatic and hepatocellular 
carcinoma [6-8]. PIM-1 and PIM-2 over expression in 
prostate cancer correlates with tumour progression [2] 
and over expression of exogenous PIM-1 or PIM-2 in 
prostate cancer cell lines increases cell proliferation [9, 
10]. The molecular mechanisms by which PIM kinases 
regulate tumour cell proliferation may include the 
phosphorylation and inactivation of cell cycle inhibitors 
p27Kip1 [10] or p21cip1 [11] or the activation of molecules 
that positively regulate cell cycle progression such as 
CDC25A, CDC25C or the kinase C-TAK1[12]. PIM 
kinases may regulate cell viability by phosphorylating Oncotarget 2011; 2:   1134 - 1144 1135 www.impactjournals.com/oncotarget
the apoptotic proteins BAD and ASK1 [13, 14] and are 
involved in the regulation of drug resistance [15]. 
 In addition to the identification of individual PIM 
substrates, the major proliferative signaling pathways 
that are regulated by PIM kinases are beginning to be 
identified. We have recently characterized a novel small 
molecule designated M-110, as a highly selective inhibitor 
of all three PIM kinase isoforms and showed that M-110 
inhibits, through inhibition of PIM-3, but not of PIM-1 
or of PIM-2, the phosphorylation of STAT3 on tyrosine 
residue 705 in the prostate cancer derived cell line DU-
145 and the pancreatic cancer derived cell line MiaPaCa2 
[16]. STAT3 is an oncogenic transcription factor that is 
activated by phosphorylation on tyrosine residue 705 and 
the importance of STAT3 signaling in cell proliferation 
is well documented [17, 18]. STAT3 is activated by 
stimulation of IL-6 which is an important autocrine/
paracrine growth factor for prostate cancers and M-110 
was shown to interfere with IL-6 induced activation 
of STAT3. However, not all prostate cancer cell lines 
that are sensitive to M-110 treatment express activated 
STAT3. For instance the proliferation of 22Rv1 and PC3 
cells is inhibited by M-110. However, 22Rv1 cells do not 
express active STAT3 but express active STAT5 that is 
not affected by M-110 treatment [16]. PC3 cells do not 
express STAT3 because of a genomic deletion containing 
the STAT3 gene [19]. Therefore it is likely that the M-110 
induced inhibition of cell proliferation is mediated through 
inhibition of multiple proliferative pathways in a cell type 
dependent manner. 
EGFR over expression or mutations leads to 
abnormal EGFR signaling which is linked to the 
development of many tumours [20]. For instance EGFR 
expression  is  increased  in  a  significant  proportion 
of prostate cancer patients and increased expression 
correlates with increased risk of relapse and progression 
to castration resistant disease [21-23]. Binding of EGF 
to  the  EGFR  (ErbB1)  results  in  homodimerization 
or  heterodimerization  of  the  EGFR  with  any  of  three 
EGFR related receptors ErbB2-4. Dimerization leads to 
phosphorylation of a number of tyrosine residues present 
in the cytoplasmic portion of the EGFR by the intracellular 
receptor tyrosine kinase domain. Intracellular proteins 
with SH2 or phosphotyrosine binding motifs are then 
recruited to the activated tyrosine phosphorylated receptor 
to activate a number of proliferative signaling pathways 
such as the ERK MAPkinase and the PI3-kinase/AKT 
pathways. Signaling through the EGFR is limited by a 
number of negative feedback inhibitory proteins that are 
induced by EGF signaling [24]. One such protein is MIG6 
(also known as RALT or ERRFI1) that binds preferentially 
to the activated EGFR and inhibits its kinase activity 
[25,  26].  MIG6  may  also  regulate  the  internalization 
and degradation of the EGFR [27, 28]. Here we report 
that treatment of prostate cancer cells with M-110 or a 
structurally unrelated PIM kinase inhibitor SGI-1776 
increases the expression of MIG6 RNA and protein and 
inhibits EGF induced activation of the EGFR and the 
downstream ERK MAPkinase pathway. Knockdown of 
PIM-1 but not of PIM-2 or of PIM-3 up regulates MIG6 
expression. This identifies a novel biological function of 
PIM-1 as a positive co-regulator of the EGF/EGFR/ERK 
MAPkinase pathway. Furthermore we show synergistic 
effects of the EGFR tyrosine kinase inhibitor Gefitinib and 
PIM kinase inhibitors on prostate cancer cell proliferation. 
These results provide new insights into the oncogenic 
action of PIM kinases and support the development of 
PIM isoform specific inhibitors as anti-cancer agents to 
increase the efficacy of EGFR targeted chemotherapy.
RESULTS
PIM-1 regulates expression of the ERBB inhibitor 
MIG6
To identify signaling pathways that are affected by 
M-110 treatment of prostate cancer cells, we used micro 
array analyses to determine changes in gene expression 
induced by M-110 treatment of two prostate cancer 
cell lines, DU-145 and PC3. Cells were treated with 10 
µM M-110 or with vehicle only (DMSO) for 8 hrs, and 
RNA was extracted from 4 independent experiments and 
analyzed for genome wide changes in gene expression 
using Agilent 28004 Whole Human Genome expression 
microarrays. Analyses showed that the expression of 
257 probes representing genes changed > 2-fold after 
treatment of DU-145 cells with M-110 compared to 
treatment with DMSO only. In PC3 treated cells, 113 
gene expression differences were identified and 97 gene 
expression differences were common among DU-145 and 
PC3 cells Of these, 59 were up regulated and 38 were 
down regulated by M-110 treatment in both cell lines 
257            97             113
FIGURE 1
DU-145           PC3
Figure 1: Gene expression differences induced by 
M-110 treatment of prostate cancer cells. A Venn 
diagram of the number of genes responding to treatment with 10 
μM M-110 for 8 hr. Ninety seven gene changes were in common 
between DU-145 and PC3 cells. Thirty six genes were identified 
as targets of transcription factors that are regulated by PIM 
kinases (table 1).Oncotarget 2011; 2:   1134 - 1144 1136 www.impactjournals.com/oncotarget
(Figure 1 and Supplementary Table 1). RT-qPCR assays 
for expression of genes included in the 97 common gene 
set validated the microarray results for 8 genes analyzed 
(Supplementary Figure 1), showing that the microarray 
results are of high quality and can be used to predict 
M-110 induced gene expression differences in DU-145 
and PC3 cells with high confidence. 
M-110 is a selective inhibitor of PIM kinases and 
therefore we expected that a significant fraction of gene 
expression differences would involve genes that are 
targets of transcription factors that are modulated by PIM 
kinases. An extensive literature review suggest that this is 
the case because 36 genes in the 97 common gene set (~ 
40 %) affected by M-110 treatment have previously been 
identified as targets for the PIM modulated transcription 
factors c-myc [29, 30], c-myc and PIM-1 [31] , FOXO3a 
[32], c-Myb [33, 34] or RUNX1-3 [35, 36] (Table 1). 
Several genes in the common 36 gene set may contribute 
to M-110 mediated inhibition of cell proliferation, but we 
focused on the expression of MIG6, because it encodes 
an important inhibitor of EGFR signaling [37, 38], 
suggesting that M-110 treatment of prostate cancer cells 
negatively affects signaling through the EGFR. Figure 
2A shows that M-110 treatment for 8 hrs up regulates 
MIG6 RNA in PC3 and DU-145 cells, validating the 
micro array results obtained after 8 hr of treatment. We 
also included a 4 hr treatment which showed that the 
effect of M-110 treatment on the expression of MIG6 is a 
relatively early event. Treatment with M-142, an inactive 
derivative of M-110 that does not inhibit PIM kinase or 
cell proliferation [16] had no effect on the expression of 
MIG6 RNA suggesting that up regulation of MIG6 RNA 
is a consequence of M-110 mediated PIM inhibition. To 
further support the involvement of PIM kinases in the 
Transcr. 
Factor
Gene
Effect Of 
M-110 
Treatment
Symbol Du-145 PC3 Gene Name Access Number
c-MYC ARG2 4.0 2.6 up arginase, type II NM_001172
ATF3 9.9 3.3 up activating transcription factor 3 NM_001040619
CCNE2 2.7 4.2 up cyclin E2 NM_057749
CXCR4 4.1 2.7 up chemokine (C-X-C motif) receptor 4 NM_001008540
DDIT4 4.8 2.6 up DNA-damage-inducible transcript 4 NM_019058
FOS 14.2 3.7 up FBJ murine osteosarcoma viral oncogene homolog NM_005252
NDRG1 6.8 7.7 up N-myc downstream regulated 1 NM_006096
PPP1R3B 3.0 2.2 up protein phosphatase 1, regulatory (inhibitor) sub 3B NM_024607
TNFAIP3 6.5 5.9 up tumor necrosis factor, alpha-induced protein 3 NM_006290
RASFF2 4.6 7.7 up Ras associated (RalGDS/AF-6) domain family NM_014737
SOCS3 3.1 2.3 up Suppressor of cytokine signaling 3 NM_003955
CCNB1 3.7 2.3 down cyclin B1 NM_031966
CDCA8 2.0 2.5 down cell division cycle associated 8 NM_018101
CENPA 4.8 2.6 down centromere protein A NM_001809
HIST1H3B 4.3 3.4 down histone cluster 1, H3b NM_003537
NDC80 2.2 2.9 down NDC80 homolog NM_006101
NUDT6 2.4 2.5 down nudix NM_198041
PLK1 7.5 2.9 down polo-like kinase 1 (Drosophila) NM_005030
c-MYC/PIM-1 ADM 13.9 5.3 up adrenomedullin NM_001124
BTN2A1 8.6 6.5 up butyrophilin, subfamily 2, member A1 NM_078476
FOSB 19.1 2.9 up FBJ murine osteosarcoma viral oncogene homolog B NM_006732
GADD45B 2.7 2.8 up growth arrest and DNA-damage-inducible, beta NM_015675
STARD4 2.1 2.8 up StAR-related lipid transfer (START) domain containing 4NM_139164
FOXO3a DUSP1 3.3 7.0 up dual specificity phosphatase 1 NM_004417
GADD45A 3.8 2.3 up growth arrest and DNA-damage-inducible a NM_001924
MXI1 5.1 4.2 up MAX interactor 1 NM_130439
AURKA 3.2 2.4 down aurora kinase A NM_198433
NEK2 2.2 2.1 down NIMA  related kinase 2 NM_002497
H1F0 2 2.7 down Histone H1 NM_005318
c-myb CCNB1 3.9 3.0 down cyclinB1 NM_031966
FGF2 2.3 3.0 down Fibroblast Growth factor-2 NM_002006
TOP2a 3.6 2.2 down topoisomarase2 NM_001067
RUNX MIG6 2.2 3.0 up ERBB  receptor feedback inhibitor 1 NM_018948
ANGPTL4 8.3 26.8 up angiopoietin-like 4 NM_139314
ENO2 4.3 2.2 up enolase 2 (gamma, neuronal) NM_001975
CYP1B1 2.1 7.0 down P450, family 1, subfamily B, polypeptide 1 NM_000104
Table 1: Description of the 36 common gene setOncotarget 2011; 2:   1134 - 1144 1137 www.impactjournals.com/oncotarget
regulation of MIG6 we also treated DU-145 and PC3 
cells with SGI-1776, a well defined PIM kinase inhibitor 
that is not structurally related to M-110 [39]. As shown in 
Figure 2A treatment of PC3 cells for 4 hr or 8 hr with 10 
μM SGI-1776 up regulates MIG6 RNA expression to a 
similar extent as treatment with M-110. Treatment of DU-
145 cells with SGI-1776 also up regulates MIG6 RNA 
after 4 hr but the response of DU-145 cells to 10 μM SGI-
1776 appears more transient than the response to 10 μM 
M-110. Nevertheless the fact that PC3 cells and DU-145 
cells up regulate MIG6 expression after treatment with 
two unrelated PIM kinase inhibitors, but not with M-142 
strongly suggests a role for PIM kinases in the regulation 
of MIG6 expression. To determine whether one or more 
PIM isoforms are involved in the regulation of MIG6 
gene expression we used PIM isoform specific siRNAs to 
selectively knockdown PIM-1, PIM-2 or PIM-3. We used 
these isoform specific PIM siRNAs previously to show 
that PIM-3 is a positive regulator of STAT3-tyrosine 705 
phosphorylation [16]. Figure 2B shows that MIG6 RNA 
is up regulated in DU-145 and PC3 cells treated with 
siPIM-1 but not in cells treated with siPIM-2, siPIM-3, 
or a control siRNA. These results show that PIM-1 but 
not PIM-2 or PIM-3 inhibits the expression of MIG6. The 
specificity of the PIM isoform specific siRNAs is shown 
in Supplementary Figure 2A. The up regulation of PIM-2 
and PIM-3 by siPIM1 has been observed before [16] but 
is unlikely to impact the conclusion that MIG6 is a PIM-1 
regulated gene as the PIM-2 and PIM-3 siRNAs have no 
effect on MIG6 expression. 
M-110 inhibits EGFR activation
The up regulation of MIG6 RNA by M-110 results 
in a robust increase in MIG6 protein as determined by 
Western blotting of M-110 and M-142 treated PC3 and 
DU-145 cells (Figure 2C). The  specificity  of  the  anti-
MIG6  antibodies  was  verified  by  analyzing  siMIG6 
treated DU-145 cells which identified MIG6 as a ~ 52Kd 
protein (Supplementary Figure 2B). To determine whether 
the MIG6 protein functions as a negative regulator of 
EGFR activation, we down regulated expression of MIG6 
RNA and tested whether this resulted in increased EGFR 
activation as measured by the expression of p-EGFRtyr1068. 
Phosphorylation of tyrosine residue 1068 correlates 
Figure 2: Regulation of MIG6 gene expression. (A) PC3 or DU-145 cells were treated for 4 hr or 8 hr with 10 μM of the indicated 
compounds and analyzed for MIG6 RNA by RT-qPCR. (B) Expression of MIG6 RNA was analyzed by RT-qPCR 40 hr after transfection of 
PC3 or DU-145 cells with PIM isoform specific siRNAs or a control siRNA. (C) DU-145 or PC3 cells were treated with M-110 or M-142 
(10 μM, 16 hr) and whole cell extracts were analyzed for expression of MIG6 protein. Tubulin was used as a loading control. (D) DU-145 or 
PC3 cells were left untreated or transfected with control or MIG6 siRNA. After treatment with 10 ng/ml EGF for 15 min whole cell lysates 
were analyzed for EGFR activation as determined by the expression of EGFR phosphorylated on tyrosine residue 1068.
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well with EGFR activation [40]. Figure 2D shows that 
treatment of DU-145 or PC3 cells with MIG6 siRNA but 
not with control siRNA resulted in increased response to 
EGF, which shows that the MIG6 protein functions as a 
negative regulator of EGFR signaling in prostate cancer 
derived cells. Therefore the M-110 induced up regulation 
of MIG6 is expected to inhibit EGFR activation in PC3 
and DU-145 cells. Supplemental Figure 3A,B shows that 
both cell lines respond robustly to EGF stimulation. To 
determine whether M-110 treatment leads to inhibition 
of EGFR activation we pre-treated PC3 or DU-145 
cells with M-110 for 16 hrs followed by 15 min of 
EGF  stimulation.  We  then  measured  both  the  changes 
in tyrosine phosphorylated EGFR as well as possible 
changes in the expression of total EGFR protein because 
of the potential for MIG6 to increase EGFR internalization 
and degradation. Treatment with M-110 before addition 
of EGF significantly inhibits the EGF induced increase 
in EGFRtyr1068 in PC3 as compared to pre treatment with 
DMSO, the vehicle for the compounds used (Figure 3A,C) 
or DU-145 cells (Figure 3D,F). Pre-treatment of PC3 and 
DU-145 cells with M-110 also reduces the expression 
of total EGFR protein (Figure 3B,C and E,F). Since the 
decrease in p-EGFRtyr1068 is greater than the decrease in 
total EGFR (P<0.05 for both cell lines) the decrease in 
activated, tyrosine phosphorylated EGFR in PC3 and DU-
145 cells may in part be due to decreased phosphorylation 
and in part to down regulation of the receptor protein. As 
expected,  pre-treatment  with  M-142  had  no  significant 
effect on subsequent EGF stimulation. To determine the 
effect of decreased EGFR activation on downstream 
signaling events, we also measured the effect of M-110 
treatment on EGF induced activation of the ERK MAP 
kinase pathway. EGF treatment of PC3 and DU-145 cells 
increases the expression of phosphorylated activated 
MEK1/2 and ERK1/2 (Supplementary Figure 3C-F) and 
treatment with M-110 but not with DMSO or M-142 
significantly inhibits the EGF induced activation of both 
components of the ERK MAPkinase pathway (Figure 4). 
Collectively these results show that M-110 inhibits EGF 
signaling through the EGFR as shown by inhibition of 
EGF induced EGFRtyr1068 expression and of EGF induced 
ERK MAPkinase pathway activation. 
Figure 3: M-110 down regulates EGFRtyr1068 expression. PC3 cells (A-C) or DU-145 cells (D-F) were treated with DMSO or with 
M-110 or M-142 (10 μM, 16 hr) followed by treatment with EGF (10 ng/ml, 15 min) and analyzed for expression of p-EGFRtyr1068 (A,D) or 
EGFR (B,E). Expression in DMSO or compound + EGF treated cells is expressed as the percentage of the expression in untreated control + 
EGF treated cells. Results are the average of 3 independent experiments. (C,F) To quantitate the expression of p-EGFRtyr1068, EGFR or actin 
equal amounts of EGF treated control samples and EGF+compound treated samples were analyzed in lanes 1 and 5-7. Lanes 2-4 contain 
two-fold serial dilutions of the control sample analyzed in lane 1 to provide a standard curve used for calculating the % change in expression 
of p-EGFRtyr1068, EGFR and actin in lanes 5-7. 
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PIM inhibitors increase the efficacy of the EGFR 
tyrosine kinase inhibitor Gefitinib
Both M-110 and SGI-1776 treatment up regulates 
MIG6 expression, which results in inhibition of EGFR 
tyrosine kinase activity. Therefore, our results suggest 
that  the  efficacy  of  EGFR  tyrosine  kinase  inhibitors 
such as Gefitinib is increased by the addition of M-110 
or SGI-1776. To test this hypothesis we first treated PC3 
and  DU-145  cells  with  Gefitinib,  SGI-1776  or  M-110 
as single agents or with combinations of Gefitinib and 
M-110 or Gefitinib and SGI-1776. The concentrations of 
the compounds used as single agents or in combinations 
were used at suboptimal concentrations close to 0.5x 
their respective IC50s for growth inhibition. The IC50s 
are shown in Table 2. Figure 5A,B shows that the effects 
of  the  combination  treatments  are  significantly  greater 
than the effects of the single agent treatments suggesting 
additive or synergistic interactions. In a second set of 
experiments we then determined whether the interactions 
between Gefitinib and the two PIM kinase inhibitors are 
synergistic or additive using the combination index (CI) 
method of Chou and Talalay [41]. Gefitinib was mixed 
with SGI-1776 or M-110 at ratios similar to those shown 
in panels A and B with the highest concentrations at 4x 
their respective IC50s. PC3 and DU-145 cells were 
then treated with two-fold serial dilutions of these drug 
combinations or of the single agents and the CI values 
were calculated at different effect levels (affected fraction 
or Fa) using the CompuSyn software developed by 
Chou and Martin. The CI-Fa plots presented in Figure 
5C,D show that the CI values are < 1 over a large range 
of Fa values indicating synergistic interactions between 
Gefitinib and SGI-1776 or M-110. It is not clear why the 
Gefitinib / PIM kinase combinations show only additive 
or even significant antagonism at low Fa values. However 
these Fa values have little potential clinical applications 
and our experiments clearly demonstrate that under 
conditions where cell proliferation is inhibited by > 80 
% Gefitinib and PIM kinase inhibitors act synergistically. 
Figure 4: M-110 down regulates EGF induced p-MEK1/2 and p-ERK1/2. PC3 cells (A,B) or DU-145 cells (C,D) were treated 
with DMSO or with M-110 or M-142 (10 μM, 16 hr) followed by treatment with EGF (10 ng/ml, 15 min) and analyzed for expression 
of p-MEK1/2 or p-ERK1/2. Expression in DMSO or compound + EGF treated cells is expressed as the percentage of the expression in 
untreated control + EGF treated cells. Results are the average of 3 independent experiments. (B,D) Quantitation of pMEK1/2, MEK1/2, 
pERK1/2 and ERK1/2 by Western blotting was as described in the legend to figure 3. 
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These  experiments  illustrate  the  biological  significance 
of our finding that MIG6 is a PIM-1 regulated gene and 
suggests a way to increase the efficacy of EGFR inhibitor 
based chemotherapy.
DISCUSSION 
Our results document two important new findings. 
First, using two structurally unrelated and highly selective 
small molecule PIM kinase inhibitors and PIM kinase 
isoform specific siRNAs we show that the regulation of 
MIG6 involves PIM-1 but not PIM-2 or PIM-3. Together 
with the negative effect of M-110 on EGFR activation this 
defines a novel biological function for PIM-1 as a positive 
co-regulator of signaling through the EGFR. Second, we 
show that PIM kinase inhibitors increase the efficacy of 
the EGFR inhibitor Gefitinib. 
  The  finding  that  PIM-1  but  not  PIM-2  or  PIM-
3 is involved in the regulation of MIG6 expression is 
significant as little is known about PIM isoform specific 
functions. Two rare examples of studies that were able to 
define PIM isoform specific functions showed that PIM-
1 but not PIM-2 regulates CXCR4 membrane expression 
[42] and that PIM-2 but not PIM-1 confers resistance 
to rapamycin mediated inhibition of IL-3 stimulated 
bone marrow cell growth [43]. The role of PIM-3 was 
not  specifically  addressed  in  these  studies.  Using  PIM 
isoform  specific  siRNAs  we  have  previously  shown 
that PIM-3 but not PIM-1 or PIM-2 is a co-regulator of 
STAT3 activation in DU-145 cells [16]. Combined with 
our current data that PIM-1 but not PIM-2 or PIM-3 is co-
regulator of EGFR activation in DU-145 and PC3 cells, 
it is evident that PIM-1 and PIM-3 can independently 
regulate two important proliferative signaling pathways 
even when expressed in the same cells. The mechanisms 
underlying the PIM-1 isoform specific regulation of MIG6 
are unknown. MIG6 is a RUNX1 regulated gene [36] and 
PIM-1 is known to phosphorylate RUNX3 in vitro and in 
HEK293 cells. PIM-1 was also shown to phosphorylate 
RUNX1 in vitro [44, 45]. The PIM-1 phosphorylation 
sites on RUNX1 have not been rigorously identified but it 
is possible that the isoform specificity is determined at the 
level of RUNX1 phosphorylation. One could speculate 
that PIM-1 and PIM-3 phosphorylate different residues 
of RUNX1 that may have different consequences for the 
activity of RUNX1. If so, the differences are likely to be 
quantitative rather than qualitative as was shown for the 
phosphorylation of the BAD protein in which different 
residues are phosphorylated by PIM-1 and PIM3 with 
PIM-1 displaying a preference for residue Ser112 and 
PIM-3 displaying a preference for Ser136 and Ser155 
[46]. However it should be noted that RUNX1 does not 
contain an amino acid sequence with high homology to 
the Lys/Arg rich PIM consensus phosphorylation site and 
Figure 5: PIM kinase inhibitors increase the efficacy of Gefitinib. (A,B) PC3 or DU-145 cells were treated with suboptimal 
concentrations of Gefitinib, SGI-1776, M-110 or combinations of Gefitinib and SGI-1776 or M-110. Cell proliferation was measured after 
72 hrs using the SRB assay. (C,D) Fa-CI plots generated according to Chou and Talalay for PC3 and DU-145 cells treated with gefitinib 
and SGI-1776 (Gef. + SGI) or Gefitinib and M-110 (Gef. + 110). The CI values are < 1 over a wide range of effects indicating synergistic 
interactions between Gefitinib and PIM kinase inhibitors.
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the phosphorylation of RUNX1 by PIM-1 at an atypical 
site may be PIM-1 specific. 
The  MIG6 gene expression is also up regulated 
by EGF/EGFR stimulation in an ERK MAPkinase 
dependent manner [47] an observation that prompted the 
classification of MIG6 as a negative feedback inhibitor of 
EGF/EGFR signaling. To rule out that the EGF induced 
up regulation of MIG6  influences  our  measurements 
of the effect of M-110 or SGI-1776 on up regulation of 
MIG6, we determined the time course of EGF induced 
MIG6 RNA expression by RT-qPCR in DU-145 and PC3 
cells and found that increases in MIG6  RNA  are  first 
detectable between 30 and 60 min after addition of EGF 
(Supplementary Figure 4). It is thus unlikely that our 
results on PIM inhibitor mediated inhibition of EGFR 
activation measured after 15 min of EGF stimulation are 
influenced by EGF up regulated MIG6. 
Consistent with the known functions of MIG6, 
down regulation of MIG6 by siRNA increased EGF 
induced activation of EGFR. Signaling through the EGFR 
is involved in many aspects of tumour development, 
contributing to cancer cell proliferation, cell survival 
and cell motility and invasion [20, 48]. For instance, 
growth of early prostate tumours is androgen dependent 
and is therefore sensitive to androgen ablation. However 
upon relapse the disease almost invariably progresses to 
castrate resistant prostate cancer (CRPC) in which prostate 
tumours acquire the capacity to grow in castrate levels 
of hormone. Expression of the EGFR is up regulated in 
CRPC [22, 23] suggesting that growth of these late stage 
tumours is at least in part driven by exaggerated signaling 
through the EGFR. Antibodies against the ligand binding 
domain of EGFR (Erbitux) or small molecules that 
inhibit  the  EGFR  tyrosine  kinase  activity  (Gefitinib, 
Erlotinib) have been developed as therapeutic agents for 
treatment of EGFR driven tumours and these reagents are 
successfully employed in the clinic, especially against 
subsets of patients with NSCLC. However the results 
of EGFR kinase inhibitors for the treatment of CRPC 
have been somewhat disappointing [49, 50]. This lack 
of in vivo efficacy is reflected by the high in vitro IC50 
values of Gefitinib for growth inhibition of DU-145 and 
PC3 cells. Thus our results that combinations of Gefitinib 
and PIM inhibitors show synergistic effects on growth 
inhibition therefore has potential therapeutic implications 
for treatment of CRPC patients since the effective dose 
of Gefitinib in combination with PIM inhibitors can be 
lowered to 2.5 μM, a concentration that may be attainable 
in plasma of patients treated with high dose once daily 
Gefitinib [51]. In addition to the potential use of Gefitinib 
/ PIM kinase inhibitor combination in the treatment of 
CRPC, this combination may be especially attractive 
in treatment of EGF driven tumours such as NSCLC in 
which Gefitinib as a single agent already has significant 
activity. Adding a PIM inhibitor leading to up regulation of 
MIG6 may have a broader effect on EGFR signaling than 
treatment with EGFR specific tyrosine kinase inhibitors 
alone because MIG6 also inhibits signaling through the 
EGFR related receptor ERBB2 [52]. Up regulation of 
ERBB2 is an important factor of the acquired resistance to 
EGFR targeted therapies. Thus addition of PIM inhibitors 
not only increases the initial efficacy of EGFR targeted 
therapies but by inhibiting HER2 may also significantly 
increase the disease free interval between treatment and 
relapse. 
The identification of PIM-1 as a positive regulator 
of EGF/EGFR signaling expands our knowledge of 
oncogenic signaling pathways that are controlled by single 
PIM kinase isoforms. This suggest that developing PIM 
isoform specific inhibitors will not only allow a further 
characterization  of  PIM  isoform  specific  functions  but 
also allow a targeted approach to cancer treatment through 
the rational design of combination therapies. 
MATERIALS AND METHODS
Microarray Analyses
200 ng of starting material for each sample as well 
as  Human  Universal  Reference  RNA  were  amplified 
and labeled with Cy5 and Cy3 dyes, respectively, and 
hybridized  to  Agilent  28004  Human  Whole  Genome 
microarrays according to the standard manufacturers 
protocols. Microarray slides were scanned on a G2565C 
DNA  Scanner  and  quantified  using  Feature  Extraction 
Software version 10.7.1.1.3 (Agilent). Quality of 
individual samples was assessed in R (v2.10) using the 
ArrayQualityMetrics Bioconductor package [53]. Data 
were then imported into GeneSpring (v11.5.1, Agilent) 
for further analyses.
Normalization  consisted  of  an  Agilent  Spatial 
Detrending normalization followed by a median centred 
“per-gene” normalization. All statistics were carried out 
on log base 2 converted data. Data were first filtered such 
that only probes that were in the upper 80th percentile of 
measured expression in 75 percent of the samples for any 
1 out of the 4 categories (PC3 or DU145 M110 treated or 
DMSO control) were used, leaving 37678 probes out of 
the 42545 probes found on the array for further analysis. 
Statistical testing consisted of a 2-way ANOVA (treatment 
type and cell type) with a Benjamini and Hochberg [54] 
multiple testing correction False Discovery Rate set 
to  p<0.05.  7988  probes  were  found  to  be  significantly 
different between the cell types and 401 were found 
between the treatment versus control category. Of the 401 
probes found different between the M110 treatment and 
DMSO control, 257 probes in the DU145 cell type and 
113 in the PC3 cell type were greater than 2 fold different 
and 97 probes were found in common between the two 
cell types. Oncotarget 2011; 2:   1134 - 1144 1142 www.impactjournals.com/oncotarget
Cell culture
DU-145 and PC3 cells were purchased from the 
American Type Culture Collection (Rockville, MD, USA) 
and grown in MEM supplemented with 10 % FCS. All 
media were supplemented with 100 units/ml of penicillin, 
0.1 mg/ml streptomycin, 2 mM glutamine and 1xMEM 
non-essential amino acids (Sigma-Aldrich, Oakville, 
Ontario, Canada). 
Reagents and Antibodies
  Compound  M-110  was  synthesized  by  Sundia 
MediTech Company (Shanghai, P.R.China). M-142 
was  synthesized  at  the  Ontario  Institute  for  Cancer 
Research  (Toronto,  ON,  Canada).  Gefitinib  and  SGI-
1776 were from Selleck Chemicals (Houston, TX, USA). 
Recombinant human EGF was from Peprotech (Montreal, 
QC,  Canada).  Antibodies  specific  for  MIG6,  EGFR, 
pEGFRtyr1068, ERK1/2, p-ERK1/2 and p-MEK1/2 were 
from Cell Signaling Technology (Danvers, MA, USA). 
Tubulin  and  MEK1/2  antibodies  were  from  SantaCruz 
Biotechnologies (Santa Cruz, CA, USA). Anti-actin was 
from Sigma-Aldrich. 
EGF stimulation
Cells (0.5x105) were plated in 12-well plates and 
allowed to adhere for 16-20 hr. Cells were then starved in 
serum free medium for 48 hrs. Compounds were added to 
the cultures during the last 16 hrs of starvation after which 
the cells were stimulated for different time intervals with 
10 ng/ml EGF. Whole cell extracts were then prepared by 
lyses in 75 µl 2xLaemmli sample buffer and analyzed by 
Western blotting. Statistical significance of differences in 
expression were determined using GraphPad InStat 3.10 
(GraphPad Software, Inc., San Diego, CA USA) by one-
way ANOVA tests with Dunnett’s post tests comparing 
results from individual compound treated samples to the 
results of M-142 or DMSO treated controls. 
siRNA transfections
DU-145 or PC3 cells (2.5x105) were transfected 
in 6-well plates with siRNAs specific for PIM-1, PIM-
2, PIM-3, MIG6 or control siRNA (FlexiTube siRNAs 
Hs_PIM1_6, Hs_PIM2_5, Hs_PIM3_1, Hs_Mig6_4 
or Ctrl_AllStars_1 siRNA respectively) from Qiagen 
Inc. (Mississauga, ON, Canada) using the HiPerFect 
transfection reagent (Qiagen). RNA expression was 
analyzed  by  Quantitative  Real-Time  PCR  40  hrs  after 
addition of siRNAs as described [16].
Cell proliferation assay and synergy 
determinations
Growth inhibition of test compounds on prostate 
cancer derived cell lines was determined using the 
Sulphorhodamine B (SRB) assay as described [55] except 
that 0.1% acetic acid was used for staining cells with SRB 
and removing unbound SRB. Synergy between Gefitinib 
and PIM kinase inhibitors was determined according to 
Chou and Talalay using the CompuSyn software (Chou, 
T.C. and Martin, N. ComboSyn, Inc. Paramus, NJ, USA. 
www.combosyn.com)
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